Study shows patients with circulating tumor DNA are at increased risk of relapse after surgery for resectable colorectal cancer

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer – Nature Medicine – Nature Medicine

Commentary: Data Support ctDNA as a Prognostic Marker for Recurrence/Benefit in Colorectal Cancer – Cancer Network

Commentary on Twitter

In the observational arm of the CIRCULATE-Japan study, among patients with stage II-IV #ColorectalCancer, those with the presence of circulating #tumorDNA post-tumor resection have a high recurrence risk & are likely to benefit from adjuvant #chemotherapyhttps://t.co/hKlRt1ZW6T

— Nature Medicine (@NatureMedicine) January 17, 2023